Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Gazeta Médica
versión impresa ISSN 2183-8135versión On-line ISSN 2184-0628
Resumen
FIGUEIREDO, Carlos M.; FREITAS, Diogo y FERREIRA, Maria do Céu. Persistent Sexual Dysfunction and Selective Serotonin Reuptake Inhibitors: Myth or Reality?. Gaz Med [online]. 2022, vol.9, n.3, pp.230-239. Epub 30-Sep-2022. ISSN 2183-8135. https://doi.org/10.29315/gm.v1i1.572.
Selective serotonin reuptake inhibitors antidepressants are psychopharmaceuticals frequently used in clinical practice in the fields of General Practice and Psychiatry for the treatment of depressive and anxiety disorders. The high prescription of this class of antidepressants results from their profile of efficacy, safety and tolerability.
It is clinically consensual that this pharmacological class can interfere with the various phases of the sexual response during antidepressant treatment. However, more and more cases have been reported in the literature, in which sexual dysfunction is not reversible after discontinuation of the drug, configuring a new persistent clinical entity, whose pathophysiological substrate is currently under intense scientific investigation. Reviewing the recent published literature in this matter and raising awareness of physicians about this new entity reveals itself as a priority with potential implications, particularly on the approach of psychiatric pathologies so prevalent in the current society.
Palabras clave : Serotonin Uptake Inhibitors/adverse effect; Sexual Dysfunction, Physiological/chemically induced.